People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...

Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...

Setting: Two tertiary academic centers. Patients: We enrolled children younger than 18 years who were admitted to the PICU within 24 hours after insertion of a central venous catheter. We excluded ...

DUBLIN--(BUSINESS WIRE)--The "Hemophilia a (Factor Viii Deficiency) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report enhances the ...

ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment ...

We enrolled 85 of 121 eligible children. Overall, 37 subjects had DVT of which 25 were incident and 12 were prevalent (Fig. 1). Of the prevalent DVT, one was in the lower extremity unrelated to a CVC.